Sarepta Therapeutics annual r&d spending
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics R&D Spending Growth & History (SRPT)
Sarepta Therapeutics's r&d spending was $1.52B for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.52B | $717.5M | +89.19% |
| 2024 | 2024-12-31 | $804.5M | −$72.9M | −8.30% |
| 2023 | 2023-12-31 | $877.4M | $297,000 | +0.03% |
| 2022 | 2022-12-31 | $877.1M | $105.9M | +13.73% |
| 2021 | 2021-12-31 | $771.2M | $48.8M | +6.76% |
| 2020 | 2020-12-31 | $722.3M | $161.4M | +28.78% |
| 2019 | 2019-12-31 | $560.9M | $159.1M | +39.58% |
| 2018 | 2018-12-31 | $401.8M | $235.1M | +141.05% |
| 2017 | 2017-12-31 | $166.7M | −$21.6M | −11.45% |
| 2016 | 2016-12-31 | $188.3M | $41.9M | +28.61% |
| 2015 | 2015-12-31 | $146.4M | $52.2M | +55.36% |
| 2014 | 2014-12-31 | $94.2M | $21.3M | +29.24% |
| 2013 | 2013-12-31 | $72.9M | $20.5M | +39.13% |
| 2012 | 2012-12-31 | $52.4M | −$14.5M | −21.63% |
| 2011 | 2011-12-31 | $66.9M | $30.9M | +85.87% |
| 2010 | 2010-12-31 | $36.0M | $11.6M | +47.45% |
| 2009 | 2009-12-31 | $24.4M | — | — |
Sarepta Therapeutics quarterly r&d spending
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $91.3M | −$113.1M | −55.35% |
| Q1 2026 | 2026-03-31 | $154.0M | −$619.5M | −80.09% |
| Q4 2025 | 2025-12-31 | $325.3M | $125.4M | +62.71% |
| Q3 2025 | 2025-09-30 | $218.9M | −$5.6M | −2.49% |
| Q2 2025 | 2025-06-30 | $204.4M | $24.7M | +13.75% |
| Q1 2025 | 2025-03-31 | $773.4M | $573.1M | +285.96% |
| Q4 2024 | 2024-12-31 | $200.0M | $4.4M | +2.27% |
| Q3 2024 | 2024-09-30 | $224.5M | $30.2M | +15.53% |
| Q2 2024 | 2024-06-30 | $179.7M | −$62.2M | −25.71% |
| Q1 2024 | 2024-03-31 | $200.4M | −$45.3M | −18.43% |
| Q4 2023 | 2023-12-31 | $195.5M | −$18.3M | −8.55% |
| Q3 2023 | 2023-09-30 | $194.3M | −$22.4M | −10.34% |
| Q2 2023 | 2023-06-30 | $241.9M | −$10.4M | −4.14% |
| Q1 2023 | 2023-03-31 | $245.7M | $51.4M | +26.48% |
| Q4 2022 | 2022-12-31 | $213.8M | $16.5M | +8.37% |
| Q3 2022 | 2022-09-30 | $216.7M | $77.6M | +55.78% |
| Q2 2022 | 2022-06-30 | $252.3M | $12.7M | +5.30% |
| Q1 2022 | 2022-03-31 | $194.3M | −$899,000 | −0.46% |
| Q4 2021 | 2021-12-31 | $197.3M | −$9.9M | −4.80% |
| Q3 2021 | 2021-09-30 | $139.1M | −$51.3M | −26.95% |
| Q2 2021 | 2021-06-30 | $239.6M | $51.1M | +27.11% |
| Q1 2021 | 2021-03-31 | $195.1M | $59.0M | +43.34% |
| Q4 2020 | 2020-12-31 | $207.2M | −$15.9M | −7.13% |
| Q3 2020 | 2020-09-30 | $190.4M | $56.5M | +42.17% |
| Q2 2020 | 2020-06-30 | $188.5M | $75.3M | +66.44% |
| Q1 2020 | 2020-03-31 | $136.1M | $45.6M | +50.35% |
| Q4 2019 | 2019-12-31 | $223.1M | $76.9M | +52.62% |
| Q3 2019 | 2019-09-30 | $133.9M | $47.4M | +54.70% |
| Q2 2019 | 2019-06-30 | $113.3M | −$9.6M | −7.80% |
| Q1 2019 | 2019-03-31 | $90.6M | $44.3M | +95.99% |
| Q4 2018 | 2018-12-31 | $146.2M | $101.8M | +228.99% |
| Q3 2018 | 2018-09-30 | $86.6M | $52.3M | +152.88% |
| Q2 2018 | 2018-06-30 | $122.8M | $63.9M | +108.54% |
| Q1 2018 | 2018-03-31 | $46.2M | $17.1M | +58.67% |
| Q4 2017 | 2017-12-31 | $44.4M | −$26.3M | −37.18% |
| Q3 2017 | 2017-09-30 | $34.2M | −$110,000 | −0.32% |
| Q2 2017 | 2017-06-30 | $58.9M | $14.6M | +32.83% |
| Q1 2017 | 2017-03-31 | $29.1M | −$9.7M | −25.00% |
| Q4 2016 | 2016-12-31 | $70.7M | $29.4M | +70.99% |
| Q3 2016 | 2016-09-30 | $34.3M | −$2.3M | −6.34% |
| Q2 2016 | 2016-06-30 | $44.3M | $15.2M | +51.98% |
| Q1 2016 | 2016-03-31 | $38.8M | −$339,000 | −0.87% |
| Q4 2015 | 2015-12-31 | $41.4M | $10.5M | +34.20% |
| Q3 2015 | 2015-09-30 | $36.7M | $14.8M | +67.82% |
| Q2 2015 | 2015-06-30 | $29.2M | $8.5M | +41.37% |
| Q1 2015 | 2015-03-31 | $39.2M | $18.3M | +87.34% |
| Q4 2014 | 2014-12-31 | $30.8M | $5.8M | +22.95% |
| Q3 2014 | 2014-09-30 | $21.9M | $765,000 | +3.63% |
| Q2 2014 | 2014-06-30 | $20.6M | $7.7M | +58.97% |
| Q1 2014 | 2014-03-31 | $20.9M | $7.1M | +51.91% |
| Q4 2013 | 2013-12-31 | $25.1M | $12.2M | +95.39% |
| Q3 2013 | 2013-09-30 | $21.1M | $10.2M | +93.21% |
| Q2 2013 | 2013-06-30 | $13.0M | −$865,000 | −6.25% |
| Q1 2013 | 2013-03-31 | $13.8M | −$1.0M | −7.04% |
| Q4 2012 | 2012-12-31 | $12.8M | −$5.9M | −31.37% |
| Q3 2012 | 2012-09-30 | $10.9M | −$4.7M | −30.08% |
| Q2 2012 | 2012-06-30 | $13.8M | −$3.9M | −21.98% |
| Q1 2012 | 2012-03-31 | $14.8M | $4,000 | +0.03% |
| Q4 2011 | 2011-12-31 | $18.7M | — | — |
| Q3 2011 | 2011-09-30 | $15.6M | $6.6M | +72.31% |
| Q2 2011 | 2011-06-30 | $17.8M | $10.8M | +156.10% |
| Q1 2011 | 2011-03-31 | $14.8M | — | — |
| Q3 2010 | 2010-09-30 | $9.1M | — | — |
| Q2 2010 | 2010-06-30 | $6.9M | — | — |
Sarepta Therapeutics r&d spending trends
Over the last five fiscal years, Sarepta Therapeutics's r&d spending increased from $722.3M to $1.52B, a change of $799.7M. The latest reported quarter, Q2 2026, shows $91.3M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...